by David Randall | Dec 31, 2024 | FDA, Trending News
For Immediate Release: December 27, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Thursday, the FDA announced recommended changes to labeling for transmucosal buprenorphine products indicated...
by David Randall | Dec 23, 2024 | FDA
For Immediate Release: December 23, 2024 Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic...
by David Randall | Dec 20, 2024 | FDA
For Immediate Release: December 20, 2024 Today, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity, to be used in combination with a reduced-calorie diet...
by David Randall | Dec 20, 2024 | FDA
For Immediate Release: December 20, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA provided answers to a set of FAQs about software functions that may be described as clinical...
by David Randall | Dec 20, 2024 | FDA, RSS
For Immediate Release: December 20, 2024 The U.S. Food and Drug Administration approved Symvess, the first acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization (restoration of...
